Inclusion Criteria:

- Histologically documented gastric adenocarcinoma including adenocarcinoma of the
esophagogastric junction

- 18 ≤ age ≤ 70

- ECOG performance status of 0 - 2

- At least one definite measurable lesion(s): ≥ 1 cm on spiral CT scan or ≥ 2 cm in
physical examination

- Previously untreated metastatic gastric cancer patients or relapsed gastric cancer
patients (patients with recurrence at least 6 months from the date of last
administration of adjuvant chemotherapy and/or radiation therapy with 5-FU and/or
leucovorin containing regimen will be included in the study)

- Written informed consent

- Minimum life expectancy of 12 weeks

- Adequate liver, renal, bone marrow functions as evidence by the following; Absolute
neutrophil count > 1.5 x 109/L; platelets > 100 x 109/L; ASAT and/or ALAT < 3 UNL;
serum creatinine ≤ 1.5 ULN

Exclusion Criteria:

- Any other malignancies within the past 5 years except skin basal cell cancer or CIS
of cervix

- Serious comorbid diseases

- Pregnancy or lactation

- Previous history of drug allergy to one of the drugs in the study regimen